Introduction {#Sec1}
============

Maternal obesity and gestational diabetes mellitus (GDM) is a growing public health problem worldwide \[[@CR1]\]. The Institute of Medicine (IOM) developed guidelines for gestational weight gain (GWG) during pregnancy; however, no specific recommendations could be made for GDM and multiethnic differences \[[@CR2], [@CR3]\]. Both pre-pregnancy obesity and excessive GWG are related to increased risk of maternal obesity and GDM \[[@CR3]\]. Becoming pregnant or gaining too much weight during pregnancy are the risk factors for adverse perinatal complications and increased risk for future metabolic disease in overweight/obese women, both for the mothers and their offspring \[[@CR1], [@CR4]\]. Pre-pregnancy obesity and excessive GWG may have additive negative impact on maternal and neonatal outcomes in women with GDM \[[@CR5], [@CR6]\]. Pre-pregnancy obesity, gestational diabetes, and excessive GWG are associated with multiple factors such as the environment, behavior, and genetics; however, understanding these associations is complex \[[@CR1], [@CR3]\]. Diabetes-related or maternal and/or fetal adiposity-related genetic variants have been associated with GDM, pre-pregnancy weight, and GWG during pregnancy \[[@CR7]--[@CR9]\]. Kawai et al. reported that common type 2 diabetes risk variants were associated with increased risk of GDM \[[@CR8]\]. Genetic variants were associated with GDM and progression to pre-diabetes and type 2 diabetes mellitus in women with prior GDM \[[@CR9]\]. Evidence has been presented for a genetic predisposition to GDM risk and also a change in GWG during pregnancy \[[@CR7], [@CR10]--[@CR13]\], and gene--environment interactions could explain the variation in GWG and GDM.

The fat mass and obesity-associated gene (*FTO*) rs9939609 single nucleotide polymorphism (SNP) was associated with increased risk of obesity and type 2 diabetes, as well as GDM \[[@CR10]\]. The *FTO* SNPs have been reported to be associated with pre-pregnancy obesity \[[@CR8]\] and excessive GWG \[[@CR11]\]. The *FTO* variants related to type 2 diabetes are mediated by the effect of the FTO gene on body mass index (BMI); however, the exact mechanisms of this relation have not been identified \[[@CR10], [@CR11]\]. Vitamin D shows its cellular activity by binding to vitamin D receptors (VDR). VDR, as a transcription factor, has a role in the regulation of insulin secretion from pancreatic beta cells \[[@CR14]\]. VDR has effect on proliferation, differentiation, and activation of immune cells and cytokine production, and subsequently type 2 diabetes occurs \[[@CR15], [@CR16]\]. Hepatocyte nuclear factor 1A (HNF1A), as a transcription factor, has a role in the function of pancreas beta cells \[[@CR17]\]. Endocrine and exocrine pancreatic cells express HNF1A in the developmental stage. HNF1A is necessary for the glucose response to insulin secretion and glucose metabolism \[[@CR18]\]. Women with *HNF1A* mutation are diagnosed as having monogenic form of diabetes type 3 (MODY3), and these women usually present with GDM, and diabetes persisting after delivery \[[@CR17]--[@CR19]\].

This is the first study to investigate the effect of *HNF1A* gene, *VDR* gene, and *FTO* gene variants on having GDM, pre-pregnancy obesity, and excessive GWG in Turkey. We aimed to examine whether these genetic variants would associate with having GDM, and then, whether the genetic variants that associated with GDM would associate with adiposity including pre-pregnancy obesity and excessive GWG. The *VDR* gene (encoding as SNPs p.BsmI, p.ApaI, p.TaqI, and p.FokI), and, *HNF1A* gene (encoding as SNPs p.I27L, p.A98V, and p.S487N) were chosen because these genetic variants have been reported to be associated with type 2 diabetes, as well as GDM risk \[[@CR12], [@CR14]--[@CR20]\]. We also investigated the obesity-related *FTO* gene rs9939609 SNP because it is associated with both GDM and gestational body weight during pregnancy \[[@CR10], [@CR13], [@CR20]\]. Genetic variants are implicated in the pathogenesis of GDM. Evidence suggests the genetic alterations in genes responsible for metabolic changes during pregnancy predispose to GDM \[[@CR7]\]. We also hypothesized that these diabetes and adiposity-related genetic variants would likely be associated with GDM risk and gestational body weight during pregnancy.

Patients and methods {#Sec2}
====================

Study population {#Sec3}
----------------

Pregnant women referred to tertiary hospital, Obstetrics and Gynecology Clinic, Ankara, from 2015 to 2016, were included in this case-control study. Women with GDM (n = 160) and age- and gestational age-matched women without GDM as controls (n = 145) were included in the study. Gestational age was assessed from the date of the last menstrual period and clinical assessment. A 2-h, 75-g oral glucose tolerance test at 24 to 28 weeks gestation age was performed for all pregnant women, irrespective of family history of DM or any other risk factors for GDM. Glucose concentrations after fasting, and 1 and 2 h after glucose administration \< 92 mg/dl, \< 180 mg/dl, and \< 153 mg/dl, respectively, were considered normal. When the pregnant women's glucose concentration was higher than any of these values, the women were diagnosed as having GDM \[[@CR12]\]. Women whose GDM was diagnosed according to these criteria, aged 22--38 years, and whose pregnancy age was 24--48 weeks were included in the study. Women with GDM who had pre-existing type 2 diabetes, GDM observed in prior pregnancy, GDM with chronic disease such as hypertension, thyroid disorders, cardiac, hepatic or renal dysfunction were excluded. Women aged 22--38 years and with pregnancy age 24--28 weeks, with no GDM, type 2 diabetes, hypertension, thyroid disorders, cardiac, hepatic or renal dysfunction were accepted as controls and included in the study. Treatment of diet with or without insulin therapy was recorded. Weight, height, and systolic (SBP) and diastolic blood pressure (DBP) were measured in all participants. Body mass index (BMI, kg/m^2^) was calculated as weight (kg)/height^2^ (m^2^). Women were categorized as underweight (BMI \< 18.5 kg/m^2^), normal weight (BMI = 18.5--24.9 kg/m^2^), overweight (BMI = 25--29.9 kg/m^2^), and obese (BMI ≥ 30 kg/m^2^). Maternal weight before pregnancy, pre-pregnancy weight, was obtained through a questionnaire. Maternal weight was measured at delivery. Gestational weight gain (GWG) was calculated as the difference between the maternal weight at delivery and pre-pregnancy weight. The recommended GWG was calculated based on IOM guidelines related with pre-pregnancy BMI: underweight, a gain of 12.5--18 kg; normal weight, a gain of 11.5--16 kg; overweight, a gain of 7--11.5 kg; and obese, a gain of 5--9 kg. After this, GWG was divided into three categories: low, if the weight was below the recommendation; adequate, if the weight gain was within the recommendation; and high, if the weight gain was above the recommendation \[[@CR21]\]. Serum glucose, insulin, and glycated hemoglobin (HbA~1c~) concentrations were measured at 24--28 weeks of pregnancy. Insulin resistance was calculated using the homeostasis model assessment-insulin resistance (HOMA-IR): \[fasting plasma insulin (µIU/ml) × fasting plasma glucose (mg/dl)\]/405 \[[@CR12]\]. This study was approval by Diskapi Yildirim Beyazit Teaching and Training Research Hospital Ethics Board (Number. 24.04.2015-13/25). Written informed consent was obtained from each participant.

Genotyping {#Sec4}
----------

Genetic analyses for the *VDR* gene SNPs p.*FokI* (rs2228570), p.*BsmI* (rs1544410), p.*ApaI* (rs7975232), and p.*TaqI* (rs731236) and the *HNF1A* gene SNPs *p.S487N* (rs2464196, p.Ser486Asn), *p.A98V* (rs1800574, p.Ala98Val), *p.I27L* (rs1169288, p.Ile27Leu) and the *FTO* gene rs939609 SNPs were performed using real-time polymerase chain reaction (RT-PCR) amplification. Genomic DNA was isolated from collected peripheral blood samples of the subjects using DNA Isolation Kit (Roche Diagnostics, Indianapolis, IN, USA). Genotyping of each SNP in the *VDR* gene, *HNF1A* gene, and *FTO* gene was independently conducted using a pre-validated fluorescence-based allele-specific PCR assay, KASPar (KBiosciences, Hoddesdon, UK) and performed on a Rotor-Gene Q real-time cycler (Qiagen, Hilden, Germany) according to the manufacturer's instruction. Allele discrimination was made using Rotor-Gene Q software *v.*2.3.1 (Qiagen, Hilden, Germany). The genotype calling was performed blind without information on the clinical phenotypes.

Statistical analysis {#Sec5}
--------------------

Statistical analysis was performed using the SPSS 18.0 (SPSS, Inc) software. Variables are presented as mean ± standard deviation (SD) or median (min--max), percentages (%), odds ratios (OR), 95% confidence intervals (CI). Normality was tested using the Kolmogorov--Smirnov and Shapiro--Wilk *W* test. SNPs are expressed as allelic frequency (q) or prevalence of genotypes (%). Categorical variables were analyzed using the Chi-square test or Fisher's exact test, where appropriate. Student's *t*-test was used for normally distributed continuous variables or log-transformed variables between two groups. The Hardy--Weinberg equilibrium (HWE) at individual loci was assessed using the Chi-square test. Multiple logistic regression analysis and the Chi-square test or Fisher's exact test was tested using models and ORs were calculated: dominant (major allele homozygotes vs. heterozygotes + minor allele homozygotes), recessive (major allele homozygotes + heterozygotes vs. minor allele homozygotes) and codominant (major allele homozygotes vs. heterozygote and minor allele homozygotes vs. major allele homozygotes). Pair-wise linkage disequilibrium (LD) and correlation coefficients (r^2^) were analyzed using the HAPLOVIEW program. We made a variable reflecting all possible combinations of genotypes for each SNP. Power analysis was performed using web-based software <http://osse.bii.a-star.edu.sg/calculation2.php>. The power of study was 65%. Statistical significance was defined as *p *\< 0.05.

Results {#Sec6}
=======

The mean age, gestational age, and height were similar between the women with GDM and controls (p \> 0.05). Pre-pregnancy overweight/obesity were increased in women with GDM compared with controls (p \< 0.05). Weight at delivery and excessive GWG were increased in women with GDM compared with the controls (p \< 0.05). Serum glucose, insulin, HOMA-IR, and HbA1c were increased in women with GDM compared with the controls (p \< 0.05, each). The clinical features of the subjects are shown in Table [1](#Tab1){ref-type="table"}. Minor allele frequency of the *HNF1A*, *VDR*, and *FTO* genes is shown in Table [2](#Tab2){ref-type="table"}. These frequencies were in HWE except p.A98V. Haploview analysis showed that the *HNF1A, VDR*, and *FTO* genes were not in LD. The risk alleles of the *HNF1A* gene (p.S487N, and p.A98V) and, *VDR* gene (p.ApaI, p.TaqI, p.BsmI and p.FokI) were similar between women with GDM and the controls (p \> 0.05, each). Genotype analysis is shown in Table [3](#Tab3){ref-type="table"}.Table 1Characteristics of subjectsControls (n = 145)Gestational diabetes mellitus (n = 160)pAge (year)28.25 ± 5.1529.35 ± 5.360.075Gestational age (weeks)26.27 ± 1.4825.99 ± 1.650.137Height (cm)160.40 ± 5.71159.21 ± 5.950.076Pre-pregnancy weight (kg)61.74 ± 11.9876.21 ± 11.27*0.001*Pre-pregnancy BMI (kg/m^2^)24.06 ± 4.8230.21 ± 5.10*0.001*Pre-pregnancy BMI (%)*0.001* Underweight (\< 20 kg/m^2^)23.43.8 Normal weight (20--24.9 kg/m^2^)38.68.8 Overweight (25--29.9 kg/m^2^)26.234.4 Obesity (≥ 30 kg/m^2^)11.753.1Pre-pregnancy overweight/obesity (%)^a^37.987.5*0.001*Weight at delivery (kg)77.60 ± 12.5987.58 ± 11.54*0.001*BMI at delivery (kg/m^2^)30.24 ± 5.1834.71 ± 5.30*0.001*Gestational weight gain (kg)16.05 ± 5.4311.56 ± 2.72*0.001*Gestational weight gain (%)^b^*0.011* Excessive44.161.2 Adequate46.933.1 Below9.05.6Glucose (mg/dl)72.39 ± 7.12101.67 ± 11.99*0.001*İnsulin (µIU/ml)8.07 ± 2.0211.93 ± 4.78*0.001*HOMA-IR1.42 ± 0.393.06 ± 1.26*0.001*HbA1c (%)5.01 ± 0.325.51 ± 0.43*0.001*Systolic BP (mmHg)108.06 ± 8.74110.84 ± 11.230.052Diastolic BP (mmHg)72.70 ± 5.6273.48 ± 5.110.207Italics represents significant p-values*PPO* pre-pregnancy overweight/obesity, *GDM* gestational diabetes mellitus, *GWG* gestational weight gain, *BMI* body mass index, *BP* blood pressure, *HOMA-IR* homeostasis model assessment-insulin resistance, *HbA1c* hemoglobin A1c^a^Prepregnancy overweight/obesity is defined as the percentage of subjects with having BMI ≥ 25 kg/m^2b^Recommended gestational weight gain was calculated based on Institute of Medicine (IOM) recommendations according to pre-pregnancy BMI Table 2Minor allele frequency of polymorphismsRisk alleleMAF for study sampleHNF1A I27L rs1169288T0.44HNF1A S487N rs2464196T0.37HNF1A A98V rs1800574T0.10VDR ApaI rs7975232C0.42VDR TaqI rs731236C0.35VDR BsmI rs1544410G0.45VDR FokI rs2228570T0.35FTO rs9939609A0.37*MAF* minor allele frequency Table 3Genotype analysis of HNF1A gene, VDR gene and FTO gene polymorphismsControls, nGestational diabetes, nOR (95% CI)pFTO gene rs9939609 (%)*0.011*\* Co-dominant wild type TT7359  Heterozygous AT54621.42 (0.86--2.24)0.169\*\*  Homozygous AA18392.68 (1.39--4.13)*0.003*\*\*\* Dominant (AT + AA/TT)72 vs. 73101 vs. 591.73 (1.12--2.74)*0.018* Recessive (AA/AT + TT)18 vs. 12739 vs. 1212.27 (1.23--4.19)*0.007*HNF1 gene I27L rs1169288 (%)*0.009*\* Co-dominant wild type GG5033  Heterozygous GT78941.82 (1.13--3.12)*0.026*\*\*  Homozygous TT17332.94 (1.41--4.16)*0.003*\*\*\* Dominant (GT + TT/GG)95 vs. 50127 vs. 332.02 (1.21--3.38)*0.007* Recessive (TT/GT + GG)17 vs. 12833 vs. 1271.95 (1.13--3.49)*0.036*HNF1 gene S487N rs2464196 (%)0.919\* Co-dominant wild type CC6164  Heterozygous CT62721.10 (0.67--1.80)0.684\*\*  Homozygous TT22241.04 (0.52--2.04)0.910\*\*\* Dominant (CT + TT/CC)84 vs. 6196 vs. 641.11 (0.70--1.76)0.683 Recessive (TT/CT + CC)22 vs. 12324 vs 1360.98 (0.52--1.84)0.966HNF1 gene A98V rs1800574 (%)0.433\* Co-dominant wild type CC121130  Heterozygous CT22241.01 (0.54--1.90)0.962\*\*  Homozygous TT262.79 (0.55--12.45)0.196\*\*\* Dominant model (CT + TT/CC)24 vs. 12130 vs. 1301.16 (0.64--2.10)0.615 Recessive model (TT/CT + CC)2 vs. 1436 vs. 1542.78 (0.55--12.5)0.196VDR gene ApaI rs7975232 (%)0.199\* Co-dominant wild type AA5248  Heterozygous AC73781.15 (0.69--1.91)0.571\*\*  Homozygous CC20341.84 (0.93--3.62)0.076\*\*\* Dominant (AC + CC/AA)93 vs. 52112 vs. 481.30 (0.80--2.10)0.279 Recessive (CC/AA + AC)20 vs. 12534 vs. 1261.68 (0.92--3.02)0.088VDR gene TaqI rs731236 (%)0.472\* Co-dominant wild type TT8281  Heterozygous CT33371.13 (0.64--1.98)0.658\*\*  Homozygous CC30421.41 (0.80--2.48)0.222\*\*\* Dominant (CT + CC/TT)63 vs. 8279 vs. 811.26 (0.82--2.04)0.301 Recessive (CC/CT + TT)30 vs. 11542 vs. 1181.36 (0.81--2.32)0.253VDR gene BsmI rs1544410 (%)0.461\* Co-dominant wild type AA5753  Heterozygous AG52631.32 (0.78--2.24)0.290\*\*  Homozygous GG36451.37 (0.76--2.44)0.284\*\*\* Dominant (AG + GG/AA)88 vs. 57108 vs. 531.34 (0.841--2.15)0.215 Recessive (GG/AG + AA)36 vs. 10945 vs. 1161.18 (0.71--1.97)0.515VDR gene FokI rs2228570 (%)0.191\* Co-dominant wild type CC7876  Heterozygous CT43441.05 (0.62--1.77)0.855\*\*  Homozygous TT24401.71 (0.94--3.10)0.076\*\*\* Dominant (CT + TT/CC)67 vs. 7884 vs. 761.28 (0.82--2.01)0.272 Recessive (TT/CT + CC)24 vs. 12140 vs. 1201.68 (0.95--2.59)0.070Categorical variables were analyzed with Chi-square test or Fisher's exact test, where appropriate. Multiple logistic regression analysis and Fisher's exact test were tested using models: dominant (major allele homozygotes vs heterozygotes + minor allele homozygotes), recessive (major allele homozygotes + heterozygotes vs minor allele homozygotes) and codominant (major allele homozygotes vs heterozygote and minor allele homozygotes vs major allele homozygotes)Italics represents significant p-values\*p Wild vs homozygous vs heterozygous\*\*p heterozygous vs wild\*\*\*p homozygous vs wild type

The *FTO* gene rs9939609 distribution was TT-wild, heterozygote AT, and homozygote AA at 50.3%, 37.2%, and 12.4% in the controls, and 36.9%, 38.8%, and 24.4% in women with GDM (p = 0.011). The *FTO* gene AA genotype was associated with an increased risk of GDM more than the TT/AT genotype in co-dominant, dominant, and recessive models (dominant: AT + AA vs. TT-wild, 63.1% vs. 49.7%, OR = 1.73, 95% CI \[1.12--2.74\], p = 0.018, and recessive: AA vs. AT + TT, 24.4 vs. 12.4%, OR = 2.27, 95% CI \[1.23--4.19\], p = 0.007) (Table [3](#Tab3){ref-type="table"}). The *FTO* AA/AT genotype had a greater association with pre-pregnancy overweight/obesity than TT-wild genotype (p \< 0.05) (Table [4](#Tab4){ref-type="table"}). Pre-pregnancy weight (p \< 0.05) and weight at delivery (p \< 0.05) progressively increased from the AA genotype to the TT genotype. GWG was increased in AT/AA genotype compared with the TT genotype (p \< 0.05). Serum glucose, insulin, HOMA-IR, and HbA1c were higher in the AA genotype compared with the TT genotype (p \< 0.05). The *FTO* AA genotype was associated with a greater risk of pre-pregnancy overweight/obesity compared with AT/TT genotypes (OR = 1.43, 95% CI \[1.25--3.4\], p = 0.035). The *FTO* AA genotype was associated with excessive GWG risk compared with the TT and AT genotype (OR = 1.73, 95% CI \[1.62--3.15\], p = 0.034); however, this association was lost after adjusting for pre-pregnancy weight (OR = 1.1, 95% CI \[0.94--2.38\], p \> 0.05).Table 4Clinics of pregnants according to the FTO gene rs9939609 SNPTT-wild (n = 132)AT (n = 116)AA (n = 57)p\*p\*\*p\*\*\*Controls (%)55.3 (n = 73)46.6 (n = 54)31.6 (n = 18)0.169*0.003*0.060Gestational diabetes mellitus (%)44.7 (n = 59)53.4 (n = 62)68.4 (n = 39)Pre-pregnancy BMI (%)*\<* *0.0010.0010.011* Underweight (\< 20 kg/m^2^)18.210.37.0 Normal weight (20--24.9 kg/m^2^)33.316.412.3 Overweight (25--29.9 kg/m^2^)19.744.826.3 Obesity (≥ 30 kg/m^2^)28.828.454.4Pre-pregnancy overweight/obesity (%)^a^48.5 (n = 64)73.3 (n = 85)80.7 (n = 46)*\<* *0.0010.001*0.284Gestational weight gain (%)^b^*0.001\<* *0.0010.014* Below12.13.43.6 Adequate51.537.916.1 Excessive36.458.680.4Excessive GWG (%)36.4 (n = 48)58.6 (n = 68)80.4 (n = 46)*0.001\<* *0.0010.003*Pre-pregnancy weight (kg)65.79 ± 13.8069.69 ± 11.3176.78 ± 14.81*0.016\<* *0.0010.001*Pre-pregnancy BMI (kg/m^2^)25.80 ± 5.8027.46 ± 5.0330.36 ± 6.27*0.017\<* *0.0010.001*Weight at delivery (kg)78.52 ± 13.0183.84 ± 9.8090.78 ± 14.79*0.001\<* *0.001\<* *0.001*BMI at delivery (kg/m^2^)30.77 ± 5.5633.03 ± 4.7235.86 ± 6.22*0.001\<* *0.0010.001*Gestational weight gain (kg)10.93 ± 3.7712.93 ± 2.3113.98 ± 4.91*0.0290.021*0.654Glucose (mg/dl)84.64 ± 18.0188.06 ± 17.6591.64 ± 17.250.134*0.014*0.207İnsulin (µIU/ml)9.61 ± 4.3510.18 ± 3.7211.27 ± 4.890.315*0.039*0.148HOMA-IR2.16 ± 1.262.33 ± 1.182.65 ± 1.370.307*0.033*0.159HbA1c (%)5.22 ± 0.485.24 ± 0.415.41 ± 0.510.685*0.0180.027*Systolic BP (mmHg)110.41 ± 9.59108.87 ± 10.61108.77 ± 10.740.2320.2980.951Diastolic BP (mmHg)73.74 ± 5.4372.81 ± 5.0372.24 ± 5.750.1690.0900.503Italics represents significant p-values*PPO* pre-pregnancy overweight/obesity, *GDM* gestational diabetes mellitus, *GWG* gestational weight gain, *BMI* body mass index, *BP* blood pressure, *HOMA-IR* homeostasis model assessment-insulin resistance, *HbA1c* hemoglobin A1c\*p TT wild type vs heterozygote AT\*\*p TT wild type vs homozygote AA\*\*\*p heterozygote AT vs homozygote AA^a^Prepregnancy overweight/obesity is defined as the percentage of subjects with having BMI ≥ 25 kg/m^2b^Recommended gestational weight gain was calculated based on Institute of Medicine (IOM) recommendations according to pre-pregnancy BMI

The *HNF1A* gene p.I27L distribution of GG-wild, GT, and TT was 34.5%, 53.8%, and 11.7% in the controls, and 20.6%, 58.8%, and 20.6% in women with GDM (p = 0.009). The *HNF1A* gene p.I27L TT/GT genotype was associated with a greater risk of GDM in comparison with the GG genotype in co-dominant, dominant, and recessive models (dominant: GT + TT vs. GG-wild, 79.4 vs. 65.5%, OR = 2.02, 95% CI \[1.21--3.38\], p = 0.007 and recessive: TT vs. GT + GG, 20.6 vs. 11.7%, OR = 1.95, 95% CI \[1.13--3.49\], p = 0.036) (Table [3](#Tab3){ref-type="table"}). Pre-pregnancy weight, weight at delivery, and GWG were similar between p.I27L genotypes (p \> 0.05) (Table [5](#Tab5){ref-type="table"}). Glucose, HOMA-IR, and HbA1c were increased in the p.I27L TT genotype compared with the GG-wild type (p \< 0.05). Pre-pregnancy weight, weight at delivery, and GWG did not differ between the *VDR* and *HNF1A* gene carriers (p \> 0.05).Table 5Clinics of pregnant women according to the HNF1A gene p.I27LGG wild (n = 83)GT (n = 172)TT (n = 50)p\*p\*\*p\*\*\*Controls (%)60.2 (n = 50)45.3 (n = 78)34.0 (n = 17)*0.0260.003*0.153Gestational diabetes mellitus (%)39.8 (n = 33)54.7 (n = 94)66.0 (n = 33)Pre-pregnancy BMI (%)0.6530.6220.695 Underweight (\< 20 kg/m^2^)15.713.48.0 Normal weight (20--24.9 kg/m^2^)21.723.324.0 Overweight (25--29.9 kg/m^2^)33.727.934.0 Obesity (≥ 30 kg/m^2^)28.935.534.0Pre-pregnancy overweight/obesity (%)^a^62.7 (n = 52)63.4 (n = 109)68.0 (n = 34)0.9110.5320.547Gestational weight gain (%)^b^0.1120.8040.342 Below3.69.46.0 Adequate45.835.146.0 Excessive50.655.648.0Excessive GWG (%)50.6 (n = 42)55.8 (n = 96)48.0 (n = 24)0.4340.7710.329Pre-pregnancy weight (kg)67.93 ± 13.6470.12 ± 14.2868.94 ± 11.420.2470.6650.592Pre-pregnancy BMI (kg/m^2^)26.78 ± 5.7427.51 ± 6.0627.35 ± 5.240.3640.5680.870Weight at delivery (kg)81.84 ± 13.3483.56 ± 13.5081.98 ± 10.730.3380.9510.445BMI at delivery (kg/m^2^)32.25 ± 5.6632.77 ± 5.8832.50 ± 5.130.5030.7950.772Gestational weight gain (kg)14.02 ± 4.6013.67 ± 4.8313.24 ± 4.980.5830.3590.434Glucose (mg/dl)83.89 ± 17.1086.88 ± 17.6994.06 ± 18.230.203*0.0020.013*İnsulin (µIU/ml)9.52 ± 3.1610.30 ± 4.7610.64 ± 4.090.2150.1080.681HOMA-IR2.10 ± 1.012.36 ± 1.372.54 ± 1.230.155*0.045*0.470HbA1c (%)5.15 ± 0.405.29 ± 0.505.32 ± 0.41*0.0480.037*0.736Systolic BP (mmHg)109.93 ± 10.07109.27 ± 10.26109.70 ± 10.370.6260.8960.797Diastolic BP (mmHg)73.20 ± 5.4773.11 ± 5.2672.94 ± 5.630.9010.7900.838Italics represents significant p-values*PPO* pre-pregnancy overweight/obesity, *GDM* gestational diabetes mellitus, *GWG* gestational weight gain, *BMI* body mass index, *BP* blood pressure, *HOMA-IR* homeostasis model assessment-insulin resistance, *HbA1c* hemoglobin A1c\*p wild GG vs heterozygote GT\*\*p wild GG vs homozygote TT\*\*\*p heterozygote GT vs homozygote TT^a^Prepregnancy overweight/obesity is defined as the percentage of subjects with having BMI ≥ 25 kg/m^2b^Recommended GWG was calculated based on Institute of Medicine (IOM) recommendations according to pre-pregnancy BMI

Discussion {#Sec7}
==========

Both the *FTO* AA genotype and *HNF1A* p.I27L GT/TT genotype were associated with an increased risk of having GDM in Turkish women. However, the *VDR* gene (p.ApaI, p.TaqI, p.FokI, p.BsmI) and *HNF1A* gene (p.A98V, p.S487N) were not associated with having GDM. Insulin resistance and impaired glucose metabolism was observed in both p.I27L TT and *FTO* AA genotype carriers. The *FTO* AA genotype was associated with an increased risk for pre-pregnancy overweight/obesity, but not associated with excessive GWG after adjusting for pre-pregnancy weight. The association of the adiposity-related gene FTO with GDM might be mediated by the effect of FTO on pre-pregnancy obesity. The diabetes-related p.I27L gene was associated with GDM by increasing insulin resistance.

Our results demonstrated that the *VDR* gene p.ApaI, p.TaqI, p.BsmI, and p.FokI genotypes were not associated with having GDM in Turkish women. The *VDR* gene and *HNF1A* gene SNPs were not associated with pre-pregnancy weight, weight at delivery, and GWG during pregnancy. The associations of the *VDR* gene and *HNF1A* gene with pre-pregnancy weight, weight at delivery, and GWG have not been investigated in previous studies. El-Beshbishy et al. reported that p.BsmI and p.FokI were not associated with GDM in Saudi women \[[@CR22]\]. Incompatible to our results, p.FokI \[[@CR23]\], p.ApaI, and p.TaqI \[[@CR22]\] were associated with an increased risk of GDM in Iranian women \[[@CR24]\]. We found that the *HNF1A* gene p.A98V and p.S487N were not associated with GDM in Turkish women. Zurawek et al. reported that p.I27L, p.A98V, and p.S487N were not associated with GDM in Polish women \[[@CR25]\]. No relationship was reported between p.A98V and GDM in Danish women \[[@CR12]\]; however, insulin secretion was decreased in p.A98V carriers without GDM \[[@CR26]\], which is compensated by increasing insulin sensitivity \[[@CR27]\]. Our data show that the *HNF1A* gene p.I27L GT/GG genotype was associated with an increased risk of GDM (OR = 2.02, 95% CI \[1.21--3.38\], p = 0.007). Pre-pregnancy weight, weight at delivery, and GWG were not associated with p.I27L genotypes. Insulin resistance and impaired glucose metabolism was observed in p.I27L TT carriers. We suggest that the diabetes-related p.I27L gene was associated with the increased risk of GDM by impairing glucose metabolism and increasing insulin resistance. Similarly, p.I27L was associated with an increased GDM risk in Scandinavian women by the effect of p.I27L on pancreas beta cell function \[[@CR28]\] and insulin resistance \[[@CR29]\]. Decreased beta cell function/transcriptional activity, decreased glucose-stimulated insulin secretion, increased insulin resistance, and increased type2 diabetes risk have been found in p.I27L + p.S487N carriers (if also including p.A98V) \[[@CR27], [@CR30], [@CR31]\]. HNF1A controls beta cell function by regulating target genes such as glucose transporter 2, liver pyruvate kinase, collectrin, hepatocyte growth factor activator, and *HNF4A*. Decreased HNF1A activity causes decreased beta cell mass and expression of these target genes, which lead to impaired insulin secretion \[[@CR17], [@CR18]\]. Beta-cell dysfunction is more prone to developing impaired glucose tolerance during pregnancy \[[@CR28]\].

The *FTO* gene AA genotype was associated with an increased risk of having GDM (OR = 2.27, 95% CI \[1.23--4.19\], p = 0.007). The *FTO* AA genotype had a greater risk for pre-pregnancy overweight/obesity (OR = 1.43, 95% CI \[1.25--3.4\], p = 0.035). The *FTO* AA genotype was not associated with GWG after adjusting for pre-pregnancy weight (OR = 1.1, 95% CI \[0.94--2.38\], p \> 0.05). Insulin resistance and impaired glucose metabolism were observed in *FTO* AA genotype carriers. We suggest that the adiposity-related gene *FTO* was associated with increased risk of GDM by increasing pre-pregnancy obesity. Similarly, previous studies have shown that the *FTO* rs9939609 AA genotype was associated with higher pre-pregnancy weight \[[@CR10], [@CR13], [@CR32]\]. Lawlor et al. reported that maternal fat or fetal fat adiposity-related variants were not associated with excessive GWG, but the *FTO* gene was associated with pre-pregnancy overweight \[[@CR33]\]. The *FTO* gene has a role in the regulation of adiposity-related phenotypes through the effect of FTO on weight gain during younger ages \[[@CR34]\] and continues throughout life \[[@CR10]\]. FTO is expressed in the hypothalamic region, which regulates appetite \[[@CR35]\], and this would contribute to energy intake and body fat mass \[[@CR36]\]. Our data demonstrated that *FTO* gene AA genotype carriers were heavier before pregnancy, but AA carriers did not have significant weight gain during pregnancy. Chiou et al. reported that the *FTO* gene was associated with pre-pregnancy obesity and a tendency to gain less weight throughout pregnancy \[[@CR5]\]. Consistent with our data, the *FTO* gene was not associated with greater GWG after adjusting for pre-pregnancy BMI in Caucasian and African-American populations \[[@CR37]\]. The *FTO* gene was not associated with GWG according to the period of pregnancy in British \[[@CR33]\] and Brazilian women \[[@CR10]\]. Moreover, GWG comprises other factors such as the fetus, amniotic fluid, and placenta \[[@CR10]\]. Pregnant women have biologic, behavioral, and hormonal changes throughout pregnancy \[[@CR11]\]. Pre-pregnancy body weight shows maternal nutritional changes before conception, whereas GWG represents fetal-maternal physiologic conditions associated with genetic and nutrition factors \[[@CR1]\]. This could modify the genetic contributions of the maternal *FTO*, *HNF1A*, and *VDR* gene variants on pre-gestational weight and GWG, as well as GDM \[[@CR13], [@CR33]\]; however it is not fully known which of these conditions is more associated with these disorders.

There are some limitations in our study that should be considered. We did not report the GWG according to gestational weeks. The small sample size resulted in a lower power for investigating a significant effect of any of the *HNF1A*, *VDR*, and *FTO* gene SNPs on weight changes during pregnancy. Also, we did not control our data for confounding variables such as nutrition, education, smoking and parity.

Conclusion {#Sec8}
==========

Both the *FTO* AA genotype and *HNF1A* p.I27L GT/TT genotype were associated with increased GDM risk in Turkish pregnant women. However, the *VDR* gene p.ApaI, p.TaqI, p.FokI, p.BsmI and the *HNF1A* gene p.A98V, p.S487N genotypes were not associated with having GDM. The diabetes-related p.I27L gene was associated with GDM by increasing insulin resistance. The diabetes-related *HNF1A* p.I27L gene was associated with insulin resistance, which might contribute to developing GDM. The *FTO* AA genotype was associated with pre-pregnancy overweight/obesity, but did not contribute to significant weight gain during pregnancy. The adiposity-related gene *FTO* was associated with GDM by the effect of FTO on pre-pregnancy obesity. The *FTO* gene was associated with pre-pregnancy obesity, which might contribute to developing GDM. Genetic factors involved in GDM, pre-pregnancy weight, and GWG should be identified for the prevention of adverse complications of GDM and obesity during pregnancy. Further studies with multiethnic and larger populations are needed to find genetic variants related to GDM, pre-pregnancy obesity, and GWG during pregnancy.

GDM

:   gestational diabetes mellitus

GWG

:   gestational weight gain

BMI

:   body mass index

SNPs

:   single nucleotide polymorphisms

IOM

:   Institute of Medicine

HNF1A

:   hepatocyte nuclear factor 1α

FTO

:   the fat mass and obesity associated gene

VDR

:   vitamin D receptor

HOMA-IR

:   homeostasis model assessment-insulin resistance

HbA1c

:   hemoglobin A1c
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